National Institutes of Health: Hepatitis B trials

The registry lists 42 Hepatitis B studies with National Institutes of Health as lead sponsor. 1 are open to participants now and 8 have results posted.

Phase 1 3Phase 2 16Phase 3 8Phase 4 1No phase 16(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Evaluation of Patients With Liver DiseaseRecruitingNCT00001971
• B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-BCompletedNCT04193189Phase 3Results posted
• HEPLISAV-B Hepatitis B Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's-Tyrosine Kinase Inhibitor (BTK-I)CompletedNCT03685708Phase 2Results posted
• Add-on Peginterferon Following Nucleos(t)Ide Analogue TreatmentCompletedNCT02364336Phase 2Results posted
• Combination Therapy of Pegylated Interferon Alfa-2a and Tenofovir Versus Tenofovir Monotherapy in Chronic Hepatitis BCompletedNCT01369212Phase 3Results posted
• Combination Entecavir and Peginterferon Therapy in HBeAg-Positive Immune-Tolerant Adults With Chronic Hepatitis BTerminatedNCT01369199Phase 3Results posted
• Entecavir/Pegylated Interferon in Immune Tolerant Children With Chronic Hepatitis B Virus (HBV) InfectionCompletedNCT01368497Phase 3Results posted
• Tenofovir Alone Versus Tenofovir With Emtricitabine to Treat Chronic Hepatitis BTerminatedNCT00524173Phase 2Results posted
• Lamivudine and Adefovir to Treat Chronic Hepatitis BCompletedNCT00023309Phase 2Results posted
• Optimizing HBV Care Cascade Among Foreign-Born in the United States (FOCUS-HBV Study)CompletedNCT05621304
• Study of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIVCompletedNCT05551273Phase 2
• Safety and Immunotherapeutic Activity of Cemiplimab in Participants With HBV on Suppressive Antiviral TherapyWithdrawnNCT04046107Phase 1/2
• Hepatitis B Immune Globulin (HBIg) to Restore Immune Control in People With Chronic Hepatitis BWithdrawnNCT03575208Phase 2
• Effectiveness of the Hepatitis B Vaccine Post-Hematopoietic Stem Cell TransplantCompletedNCT03511794
• Hepatitis B Reactivation During Treatment With Direct-Acting Antiviral Agents for Chronic Hepatitis C InfectionCompletedNCT03248622
• Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid TumorsCompletedNCT02143401Phase 1
• Withdrawal of Therapy After Long-Term Antiviral Treatment for Chronic Hepatitis BCompletedNCT01581554
• Long-Term Study of Liver Disease in People With Hepatitis B and/or Hepatitis C With or Without HIV InfectionCompletedNCT01350648
• Duration of Long-term Immunity After Hepatitis B Virus ImmunizationCompletedNCT01182311
• An Hepatitis B Vaccine Model for HIV Vaccine Trials in Drug UsersCompletedNCT00841477Phase 3
• Hepatitis B and HIV Co-Infection in Patients in UgandaCompletedNCT00782158
• Genes Involved in Resistance or Susceptibility to Hepatitis B VirusCompletedNCT00342186
• Safety and Effectiveness of an Adjuvant in Improving Immune Response to Hepatitis B Virus Vaccine in HIV Infected IndividualsCompletedNCT00272493Phase 2
• Pilot Study Freeze and Transport Immune CellsCompletedNCT00138268
• Pentavalent DTaP-Hep B-IPVCompletedNCT00133445Phase 2
• Long-Term Lamivudine Therapy for Chronic Hepatitis BCompletedNCT00120354Phase 4
• Safety and Acceptability of a Vaginal MicrobicideCompletedNCT00111943Phase 2
• Safety of and Immune Response to a Hepatitis B Virus Vaccine Given With a Booster (CpG7909 ODN) in HIV Infected and HIV Uninfected PeopleCompletedNCT00100633Phase 1/2
• Retrovirus Epidemiology Donor Study-II (REDS-II)CompletedNCT00097006
• Prevention of Recurrent Hepatitis B After Liver TransplantationCompletedNCT00059267
• Treatment of Hepatitis B Virus (HBV) Before Beginning Anti-HIV Drugs in Patients With Both HBV and HIVWithdrawnNCT00051090Not applicable
• Treatment of Hepatitis in Patients Who Are Triple-Infected With HIV, Hepatitis B Virus (HBV), and Hepatitis C Virus (HCV)WithdrawnNCT00051077Phase 2
• A Comparison of Adefovir and Tenofovir for the Treatment of Lamivudine-Resistant Hepatitis B Virus in People With HIVCompletedNCT00033163Phase 2
• Lamivudine and Adefovir to Treat Chronic Hepatitis B Infection in People With and Without HIV InfectionCompletedNCT00023153Phase 3
• Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV DrugsCompletedNCT00013871Not applicable
• Adefovir Dipivoxil to Treat Hepatitis B in HIV-Infected PatientsCompletedNCT00013702Phase 2
• Epidemiology, Infectivity and Natural History of Hepatitis C Virus InfectionCompletedNCT00004850
• Frequency of Parenteral and Non-Parenteral Exposures to Blood Among Healthcare Workers at the Clinical Center, NIH and at Seven Academic Hospitals in JapanCompletedNCT00001712
• Lamivudine for Chronic Hepatitis BCompletedNCT00001457Phase 2
• The Tolerance of HIV-Infected Patients With Herpes Group Virus Infections to Oral Doses of FIAUCompletedNCT00000654Phase 2
• Hepatitis B Vaccine Clinical TrialCompletedNCT00000583Phase 3
• Interruption of Maternal-to-Infant Transmission of Hepatitis B by Means of Hepatitis B Immune GlobulinCompletedNCT00000580Phase 3